CY1122968T1 - Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο - Google Patents
Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικοInfo
- Publication number
- CY1122968T1 CY1122968T1 CY20201100384T CY201100384T CY1122968T1 CY 1122968 T1 CY1122968 T1 CY 1122968T1 CY 20201100384 T CY20201100384 T CY 20201100384T CY 201100384 T CY201100384 T CY 201100384T CY 1122968 T1 CY1122968 T1 CY 1122968T1
- Authority
- CY
- Cyprus
- Prior art keywords
- axl
- cancer
- another embodiment
- active ingredient
- diamino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- -1 CARBOXAMIDE COMPOUND Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 230000004913 activation Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
[Πρόβλημα] Η παροχή: μίας φαρμακευτικής σύνθεσης για την αγωγή ενός καρκίνου που σχετίζεται με την ΑΧL• σε μία άλλη υλοποίηση, μίας ιατρικής σύνθεσης για την αγωγή ενός καρκίνου με υψηλή έκφραση της ΑΧL• και, σε μία άλλη ακόμη υλοποίηση, μίας ιατρικής σύνθεσης για την αγωγή ενός καρκίνου ο οποίος έχει αποκτήσει αντοχή, μέσω της ενεργοποίησης της ΑΧL έναντι της θεραπείας με έναν αντικαρκινικό παράγοντα. [Λύση] Ως τα αποτελέσματα εξέτασης των ενώσεων με ανασταλτική δράση έναντι της ΑΧL, οι εφευρέτες της παρούσας επιβεβαίωσαν ότι συγκεκριμένες ενώσεις διαμινο-ετεροκυκλικού καρβοξαμιδίου έχουν ανασταλτική δράση έναντι της ΑΧL και ότι φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν μία τέτοια ένωση ως δραστικό συστατικό έχουν θεραπευτική δράση επί ενός καρκίνου που σχετίζεται με την ΑΧL, επί ενός καρκίνου με υψηλή έκφραση της ΑΧL σε μία άλλη υλοποίηση, και επί ενός καρκίνου ο οποίος έχει αποκτήσει αντοχή, μέσω της ενεργοποίησης της ΑΧL, έναντι της θεραπείας με έναν αντικαρκινικό παράγοντα σε μία άλλη ακόμη υλοποίηση, ολοκληρώνοντας κατ’ αυτόν τον τρόπο την παρούσα εφεύρεση
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122968T1 true CY1122968T1 (el) | 2021-10-29 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100384T CY1122968T1 (el) | 2014-02-04 | 2020-04-28 | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (el) |
| EP (1) | EP3103453B1 (el) |
| JP (1) | JP6390626B2 (el) |
| KR (1) | KR102322338B1 (el) |
| CN (3) | CN105939714A (el) |
| AU (1) | AU2015215578B2 (el) |
| BR (1) | BR112016017897A8 (el) |
| CA (1) | CA2938818C (el) |
| CY (1) | CY1122968T1 (el) |
| DK (1) | DK3103453T3 (el) |
| EA (1) | EA033304B1 (el) |
| ES (1) | ES2788390T3 (el) |
| HR (1) | HRP20200662T1 (el) |
| HU (1) | HUE049437T2 (el) |
| IL (1) | IL247077B (el) |
| LT (1) | LT3103453T (el) |
| ME (1) | ME03775B (el) |
| MX (1) | MX363543B (el) |
| MY (1) | MY193536A (el) |
| PH (1) | PH12016501527B1 (el) |
| PL (1) | PL3103453T3 (el) |
| PT (1) | PT3103453T (el) |
| RS (1) | RS60150B1 (el) |
| SG (1) | SG11201606413RA (el) |
| SI (1) | SI3103453T1 (el) |
| SM (1) | SMT202000214T1 (el) |
| TW (1) | TWI655945B (el) |
| UA (1) | UA120607C2 (el) |
| WO (1) | WO2015119122A1 (el) |
| ZA (1) | ZA201605379B (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY193536A (en) * | 2014-02-04 | 2022-10-18 | Astellas Pharma Inc | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| DK3318259T3 (en) | 2015-07-03 | 2023-03-06 | Astellas Pharma Inc | Stabil farmaceutisk sammensætning til oral indgivelse |
| EP3372231B1 (en) * | 2015-11-04 | 2021-09-15 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy purposes and/or immunostimulation purposes which contains diamino heterocyclic carboxamide compound as active ingredient |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
| PE20242008A1 (es) | 2021-12-30 | 2024-10-03 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110110923A1 (en) * | 2008-02-12 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Fish assay for eml4 and alk fusion in lung cancer |
| US8815906B2 (en) | 2008-03-19 | 2014-08-26 | Chembridge Corporation | Tyrosine kinase inhibitors |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| PL2428508T3 (pl) * | 2009-05-08 | 2016-05-31 | Astellas Pharma Inc | Diaminoheterocykliczny związek karboksyamidowy |
| CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| RU2014121820A (ru) * | 2011-11-21 | 2015-12-27 | Иммьюноджен, Инк. | Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством |
| UA113204C2 (xx) * | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| DK2922872T3 (da) * | 2012-11-21 | 2019-01-02 | Janssen Biotech Inc | Bispecifikke egfr/c-met-antistoffer |
| MY193536A (en) * | 2014-02-04 | 2022-10-18 | Astellas Pharma Inc | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| DK3318259T3 (en) * | 2015-07-03 | 2023-03-06 | Astellas Pharma Inc | Stabil farmaceutisk sammensætning til oral indgivelse |
-
2015
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja active Application Filing
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 SM SM20200214T patent/SMT202000214T1/it unknown
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active Active
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt not_active Application Discontinuation
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527B1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-24 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| CY1125358T1 (el) | Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX373187B (es) | Terapia de combinación para tratar cáncer. | |
| CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| TW201613901A (en) | New compounds | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| BR112018001292A2 (pt) | métodos para melhor liberação de agentes ativos a tumores | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| NZ761519A (en) | Nlrp3 modulators | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| BR112018075660A2 (pt) | métodos de tratamento de câncer de pâncreas | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| BR112017016333A2 (pt) | compostos anticâncer | |
| CY1122708T1 (el) | Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου |